What this means
This review looked at studies linking aging cells and their chemical signals to a heart problem called HFpEF. The authors say most of the evidence so far comes from animal or lab work, or only shows links.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of earlier studies
- Kind of research
- A summary of earlier studies
The science
- Original title
- Cellular senescence in heart failure with preserved ejection fraction: Mechanisms and therapeutic opportunities.
- Authors
- Wang J, Liu R, Zhang X et al.
- Journal
- Ageing research reviews
- Published
- Oct 12, 2026
- Study type
- Review
- PMID
- 42863579 ↗
Abstract
Heart failure with preserved ejection fraction (HFpEF) contributes to nearly 50% of the global heart failure (HF) cases, and remains a major clinical challenge because of its heterogeneous pathophysiology, substantial residual morbidity, and limited mechanism-based treatment options. HFpEF is increasingly recognized as a heterogeneous multisystem syndrome closely associated with aging, cardiometabolic comorbidities, and chronic low-grade inflammation. Cellular senescence and the senescence-associated secretory phenotype (SASP) have emerged as potential mechanisms linking several of these systemic stressors to cardiovascular dysfunction. By paracrine and endocrine communication, SASP creates a self-reinforcing circuit in the myocardium. However, the biological consequences of cellular senescence are highly context-, cell type-, and stage-dependent, and transient senescence may exert adaptive or tissue-protective effects under certain conditions. Moreover, much of the current evidence linking senescence to HFpEF remains preclinical or associative, and HFpEF-specific human data are still limited. This review systematically assesses the current evidence linking cellular senescence and SASP to HFpEF and examines the therapeutic potential and limitations of senolytics and senomorphics.
Wang J, Liu R, Zhang X et al. Cellular senescence in heart failure with preserved ejection fraction: Mechanisms and therapeutic opportunities. Ageing research reviews. 2026. doi:10.1016/j.arr.2026.103412. PMID: 42863579. https://pubmed.ncbi.nlm.nih.gov/42863579/
Related research
A drug pair tested in people with fatty liver disease and scarring
In this small trial, more people on dasatinib plus quercetin had liver scarring improve than those on placebo. The trial was small, and it does not show the drugs are safe or work for everyone.
Old, stuck cells may sometimes help cancer resist treatment
This review looks at how cells that stop dividing after cancer treatment might sometimes help tumors survive. The authors say these cells play a role only in some cases, not in every case.
How cancer treatment may age the heart and blood vessels in breast cancer patients
This review looks at how cancer treatments can leave some cells stuck in an aging state that may harm the heart. It does not prove this process causes heart damage, since other factors can also play a part.
A tea plant root extract killed aging skin cells in a lab dish
Researchers tested a tea root extract on human skin cells that had been made old in a dish. The extract killed more of the old cells than normal ones, and it also cut some inflammation signals. This does not show the extract works in people, because the tests were done in cells and skin samples.
Cell aging after cancer treatment may help or hurt tumour growth
This paper is a review of earlier research on aged cells and cancer. It says these cells may either slow or speed up tumour growth.
A review of how damaged nerves in the body repair their protective coating
This review gathers what is known about how nerve cells rebuild their coating after injury. It does not test a new treatment, and it suggests future treatments may need to be combined.
See all research on Senolytics →